Unilateral Carotid Body Resection in Resistant Hypertension
A Safety and Feasibility Trial

Krzysztof Narkiewicz, MD,a Laura E.K. Ratcliffe, BSc, MBBS,b Emma C. Hart, Ph.D.,c Linford J.B. Briant, Ph.D.,b Marzena Chrostowska, Ph.D.,a Jacek Wolf, MD,a Anna Sznydler, MD,a Dagmara Herin, MD,a Ana P. Abdala, Ph.D.,c Nathan Manghat, MD,b Amy E. Burchell, MA, BMBC,h Claire Durant, Ph.D.,b Melvin D. Lobo,d Paul A. Sobotka, MD,e Nikunj K. Patel, MBBS, MD,f James C. Leiter, MD,g Zoar J. Engelman, Ph.D.,b Angus K. Nightingale, MB, BCHIR, MD,b Julian F.R. Paton, PhDh

VISUAL ABSTRACT


HIGHLIGHTS
- First prospective feasibility and safety clinical trial on unilateral CB resection for the treatment of high blood pressure.
- In drug-resistant patients with hypertension, unilateral CB resection was feasible and safe.
- Unilateral CB resection lowered blood pressure by 26 mm Hg in 57% of patients with drug-resistant hypertension associated with a reduction in muscle sympathetic nerve activity and its baroreceptor reflex control.
- Whole drug equivalents were reduced in the responding patients.
- Responding patients had characteristics distinct to those that did not respond; these should allow patient selection for future CB modulation trials.

From the aDepartment of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland; bCardioNomics Research Group, Clinical Research & Imaging Centre, University of Bristol and University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom; cSchool of Physiology, Pharmacology & Neuroscience, Biomedical Sciences, University of Bristol, Bristol, United Kingdom; dNIHR Barts Cardiovascular Biomedical Research Unit, William Harvey Research Institute, QMUL, Charterhouse Square, London, United Kingdom; eDepartment of Internal Medicine, Division of Cardiovascular Diseases, The Ohio State University, Columbus, Ohio; fNeurosurgery, North Bristol NHS Trust, Southmead Hospital, Bristol, United Kingdom; gDepartment of Physiology and Neurobiology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire; and hCibiem, Los Altos, California. This research was supported by the National Institute for Health Research (NIHR) Biomedical Research Unit in Cardiovascular Disease at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. This paper presents independent research funded by the NIHR. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. This work was supported by Cibiem Inc. Dr. Ratcliffe has received funding for PhD studentship/clinical research provided in part by Cibiem. Des. Hart and Paton are supported by the British Heart Foundation. Dr. Briant was funded by a University Hospitals NHS Foundation Trust Research Fellowship. Dr. Abdala has served as a consultant for Neurolixis Inc.
Animal and human data indicate pathological afferent signaling emanating from the carotid body that drives sympathetically mediated elevations in blood pressure in conditions of hypertension. This first-in-man, proof-of-principle study tested the safety and feasibility of unilateral carotid body resection in 15 patients with drug-resistant hypertension. The procedure proved to be safe and feasible. Overall, no change in blood pressure was found. However, 8 patients showed significant reductions in ambulatory blood pressure coinciding with decreases in sympathetic activity. The carotid body may be a novel target for treating an identifiable subpopulation of humans with hypertension. (J Am Coll Cardiol Basic Trans Science 2016;1:313–24) © 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

In patients with hypertension, the CBs exhibit both hyper-reflexia and aberrant discharge; in sleep apnea, the activation of the CBs is, in part, responsible for the excessive sympathetic activity and hypertension associated with this condition (8). Moreover, the hypertension evoked in a rat model of sleep apnea (by chronic intermittent hypoxia), is reliant on afferent activity generated by the CBs (9), and patients with hypertension may have exaggerated peripheral chemoreflex sensitivity to hypoxia (10,11). Additionally, acute reversible inactivation of the CBs, with hypoxia, caused a transient reduction in blood pressure (BP) and muscle sympathetic nerve activity (MSNA) in patients with hypertension (12). In rats with hypertension, severing the connection between the CBs and brain lowered both arterial pressure and sympathetic activity chronically (13). These data point toward the CBs as a therapeutic target to treat sympathetically mediated diseases (14). The global clinical problem and financial burden of hypertension continues to escalate (15), and 8% to 14% of the 1 billion patients with hypertension worldwide are drug resistant or intolerant (16). Therefore, new approaches for treating drug-resistant hypertension are justified, as are studies to identify the targets/mechanisms driving hypertension. We describe the first prospective proof-of-concept, safety and feasibility study of unilateral (u) CB excision from a cohort of patients with drug-resistant hypertension. We report, secondarily, on the proportion of these patients that showed a response in BP, the hypoxic ventilatory response (HVR), and MSNA.

**METHODS**

**STUDY DESIGN AND PATIENTS.** We present pooled results from 2 independent centers in which the primary endpoints were safety and feasibility of uCB excision in patients with drug-resistant hypertension. Secondary endpoints were to assess the proportion of

---

Dr. Lobo is supported by the Barts Hospital Charity; has served as a consultant to St. Jude Medical and ROX Medical; has received speaker fees from Cardiosonic; and has received an educational grant from Medtronic. Dr. Sobotka has served as a consultant to Cibiem, Inc.; has served as Chief Medical Officer, ROX Inc., and received salary and benefits; and has Stock Options in ROX Inc. and Cibiem. Dr. Leiter has served as a paid consultant to MAXIS Medical, Inc. Dr. Engelma is an employee of Cibiem, from which he receives a salary and has been awarded stock options. Dr. Nightingale’s institution has received financial support from Cibiem to carry out research in hypertension. Dr. Paton has served as a consultant for Cibiem. Drs. Narkiewicz and Ratcliffe contributed equally to this work.

Manuscript received April 2, 2016; revised manuscript received June 6, 2016, accepted June 7, 2016.